EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263
Doxorubicin (DOX) induces endothelial cell (EC) senescence, which contributes to endothelial dysfunction and cardiovascular complications. Senolytic drugs selectively eliminate senescent cells to ameliorate senescence-mediated pathologies. Previous studies have demonstrated differences between immor...
Main Authors: | Ibrahim Y. Abdelgawad, Kevin Agostinucci, Somia G. Ismail, Marianne K. O. Grant, Beshay N. Zordoky |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/11/13/1992 |
Similar Items
-
Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐XL–BAX interaction
by: Tareq Saleh, et al.
Published: (2020-10-01) -
Effects and Related Mechanisms of the Senolytic Agent ABT-263 on the Survival of Irradiated A549 and Ca9-22 Cancer Cells
by: Kota Sato, et al.
Published: (2021-12-01) -
Clearance of senescent cells with ABT-263 improves biological functions of synovial mesenchymal stem cells from osteoarthritis patients
by: Yugo Miura, et al.
Published: (2022-06-01) -
ABT-263 Reduces Hypertrophic Scars by Targeting Apoptosis of Myofibroblasts
by: Xiaolan Yang, et al.
Published: (2021-01-01) -
Effects of senolytic drugs on human mesenchymal stromal cells
by: Clara Grezella, et al.
Published: (2018-04-01)